LH News & Events

Labcorp announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. FDA-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals and clinics. The Labcorp Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics. Throughout 2026, product names, packaging and resources will transition from MEDTOX Diagnostics to Labcorp Point of Care.

Labcorp (LH) announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AMZN) and Datavant, the platform provides access to large, diverse datasets and advanced analytics-using deidentified, privacy-protected healthcare data-designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining. The platform will complete its initial validation phase in spring 2026 and is expected to expand through 2026, incorporating additional data sources and analytical capabilities to further accelerate research insights including inflammatory diseases, cardiometabolic conditions, women's health and oncology.

Illumina (ILMN) and Labcorp (LH) announced an expanded collaboration to advance precision oncology through applications of next-generation sequencing solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.